David Gerber, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Karyopharm
    Date added:
    Date updated:
    12/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    BerGenBio
    Date added:
    Date updated:
    12/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    AstraZeneca
    Date added:
    Date updated:
    12/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Sagimet
    Date added:
    Date updated:
    12/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    Gilead
    Date added:
    Date updated:
    12/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Catalyst Therapeutics
    Date added:
    Date updated:
    12/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Janssen
    Date added:
    Date updated:
    12/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Sanofi
    Date added:
    01/03/2022
    Date updated:
    12/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Regeneron
    Date added:
    01/03/2022
    Date updated:
    12/29/2023
Return to 162 Thoracic Oncology Tumor Board Conference (051322)